← TEVA PHARMACEUTICAL INDUSTRIES LTD

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $21.9b $22.4b $18.9b $16.9b $16.7b $15.9b $14.9b $15.8b $16.5b $17.3b
Cost of Revenue $10.0b $11.8b $10.6b $9.4b $8.9b $8.3b $8.0b $8.2b $8.5b $8.3b
Gross Profit $11.9b $10.6b $8.3b $7.5b $7.7b $7.6b $7.0b $7.6b $8.1b $8.9b
Operating expenses:
Operating Income (Loss) $2.2b ($17.5b) ($1.6b) ($443.0m) ($3.6b) $1.7b ($2.1b) $433.0m ($303.0m) $2.2b
Additional Financial Items
Amortization of Intangible Assets — $1.4b $1.2b $1.1b $1.0b $802.0m $732.0m $616.0m $588.0m $581.0m
Foreign Currency Transaction Gain (Loss), before Tax — — — — — — — — — —
Goodwill, Impairment Loss — $17.1b $3.0b — $4.6b $0 $2.0b $700.0m $1.3b $0
Income (Loss) from Continuing Operations before Income Taxes, Domestic — $1.5b $1.0b $542.0m $947.0m $126.0m ($119.0m) ($767.0m) ($456.0m) ($225.0m)
Income (Loss) from Equity Method Investments — ($3.0m) ($71.0m) ($13.0m) $138.0m $9.0m $21.0m $2.0m $1.0m $15.0m
Other Income $2.2b $1.2b $291.0m $76.0m $40.0m $98.0m $107.0m $49.0m $14.0m ($18.0m)
Preferred Stock Dividends, Income Statement Impact — $260 $249 — — — — — — —
Impairments Restructuring And Others $699.0m — — — — — — — — —
Legal Settlements And Loss Contingencies $899.0m — — — — — — — — —
Asset Impairment Charges $900.0m — — — — — — — — —
Income taxes $521.0m — — — — — — — — —
Share in (profits) losses of associated companies net ($8.0m) — — — — — — — — —
Accrued dividends on preferred shares $261 — — — — — — — — —
Income before income taxes $824.0m — — — — — — — — —
Net Income (Loss) Attributable to Parent $68.0m ($16.3b) ($2.1b) ($999.0m) ($4.0b) $417.0m ($2.4b) ($559.0m) ($1.6b) $1.4b
Net Income (Loss) Available to Common Stockholders, Basic $68.0m ($16.5b) ($2.4b) ($999.0m) ($4.0b) — — — — —
Net Income (Loss) Attributable to Noncontrolling Interest — ($184.0m) ($322.0m) ($2.0m) ($109.0m) $39.0m ($53.0m) ($56.0m) ($320.0m) $7.0m
Net Income Attributable to Noncontrolling Interest ($18.0m) — — — — — — — — —
Earnings Per Share, Basic $0.07 ($16.26) ($2.35) ($0.91) ($3.64) $0.38 ($2.12) ($0.50) ($1.45) $1.23
Earnings Per Share, Diluted $0.07 ($16.26) ($2.35) ($0.91) ($3.64) $0.38 ($2.12) ($0.50) ($1.45) $1.21
Common Stock, Dividends, Per Share, Declared $0.07 $0.85 $0.00 $0.00 — — — — — —
Basic $955,000,000.00 — — — — — — — — —
Diluted $961,000,000.00 — — — — — — — — —
Weighted Average Number of Shares Outstanding, Basic — 1k 1k 1.1b 1.1b 1.1b 1.1b 1.1b 1.1b 1.1b
Weighted Average Number of Shares Outstanding, Diluted — 1k 1k 1.1b 1.1b 1.1b 1.1b 1.1b 1.1b 1.2b
Research and Development Expense $2.1b $175.0m $114.0m — — — $98.0m — — —
General and Administrative Expense — $1.5b $1.3b $1.2b $1.2b $1.1b $1.2b $1.2b $1.2b $1.3b
Selling, General and Administrative Expense $1.2b — — — — — — — — —
Business Combination, Acquisition Related Costs — $105.0m $13.0m — — — — — — —
Selling and Marketing Expense — $3.4b $2.9b $2.6b $2.5b $2.4b $2.3b $2.3b $2.5b $2.7b
Financial expenses - net $1.3b — — — — — — — — —
Interest Expense — $875.0m $920.0m $881.0m $963.0m $891.0m $930.0m $1.0b $1.0b $916.0m
Current Income Tax Expense (Benefit) — $373.0m $700.0m $885.0m $182.0m $270.0m $430.0m $333.0m $1.1b —
Other Operating Income (Expense), Net $2.2b $1.2b $291.0m $76.0m $40.0m $98.0m $107.0m $49.0m $14.0m ($18.0m)
Income Tax Expense (Benefit) — ($1.9b) ($195.0m) ($278.0m) ($168.0m) $211.0m ($638.0m) ($7.0m) $676.0m ($180.0m)

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.